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1. Introduction 
Most patients with recurrent and metastatic rectal cancer cannot be cured. Selected patients 
with local recurrence or liver and/or lung-limited metastatic disease are sometimes curable 
with radiation therapy (RT) or surgery. However, for the majority of patients, treatment is 
palliative and systemic therapy remains the mainstay treatment.  Over the last ten years, 
survival of patients with unresectable metastatic or recurrent rectal cancer has considerably 
improved. The median survival is about two years due to availability of new chemotherapy 
regimens and targeted therapies. For decades, 5-fluorouracil (5-FU) was the only active and 
available agent. Since the year 2000, irinotecan and oxaliplatin were approved. Access to all 
these three active agents strongly correlates with improved survival. More progress was 
achieved recently with the development of targeted therapies. Bevacizumab is a monoclonal 
antibody targeting the vascular endothelial growth factor (VEGF). Cetuximab and 
panitumumab are two monoclonal antibodies targeting the epidermal growth factor 
receptor (EGFR). Combinations of these different drugs are now commonly used. 
In non-curable patients, goals are improvement of survival and quality of life. The purpose 
of this chapter is to review data from clinical trials evaluating systemic therapy in 
unresectable recurrent or metastatic rectal cancer. Commonly used chemotherapy regimens 
and biologic agents will be described as well as their side effects. General principles of 
treatment and specific treatment recommendations will also be discussed.  
2. Chemotherapy 
2.1 Fluoropyrimidines 
Fluoropyrimidines have been used for the treatment of metastatic colorectal cancer (mCRC) 
for many years. 5-FU is a fluoropyrimidine that causes inhibition of thymidylate synthase 
and leads to impaired DNA synthesis. Adding folinic acid (leucovorin) intensifies the 
cytotoxic power of 5-FU stabilizing its bind to the enzyme. Different schedules of 
administration have shown clinical activity in different trials. Short-term infusional 
schedules have gained acceptance.  A French study, compared a regimen of bolus 5-FU/LV 
day 1 to 5 every four weeks to bimonthly 5-FU/LV bolus over two hours followed by a 22 
hours 5-FU infusion for two consecutive days. The infusional regimen showed better 
response rate (RR) and progression free survival (PFS). It was also associated with less 
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hematological and gastrointestinal (GI) toxicity. This “de Gramont regimen” is now a 
standard (de Gramont et al. 1997). 
The widely used oral form of fluoropyrimidine is capecitabine. It is a prodrug that needs to 
be metabolized to 5-FU by multiple sequential enzymatic reactions. In 2001, a phase 3 
randomized trial showed that use of oral capecitabine in first-line mCRC patients was more 
active than 5-FU/LV in the induction of objective tumor responses. Time to disease 
progression and survival were at least equivalent for capecitabine compared with the 5-
FU/LV arm. Capecitabine also demonstrated clinically meaningful benefits over bolus 5-
FU/LV in terms of tolerability although hand-foot syndrome was more common (Hoff et al. 
2001). Similar results were observed in another identically designed randomized study (Van 
Cutsem et al. 2001). 
Dihydropyrimidine dehydrogenase (DPD) is an important enzyme in the metabolism of 
fluoropyrimidines. It is the rate limiting enzyme in 5-FU catabolism. Patients who are 
deficient in DPD activity may have severe, even fatal toxicities such as severe diarrhea, 
mucositis and pancytopenia. For these patients, an alternative to 5-FU is raltitrexed which is 
a pure thymidylate synthase inhibitor. In a 2002 randomized study, raltitrexed showed 
similar RR and overall survival (OS) to the de Gramont regimen and was easier to 
administer, but resulted in greater toxicity (GI and hematological) and inferior quality of life 
(Maughan et al. 2002). 
Fluoropyrimidines alone had been the standard first-line treatment of mCRC until the 
development of combination regimens with irinotecan or oxaliplatin. Fluoropyrimidine 
monotherapy remains a valid option for patients with contraindications to combined 
therapies. The infusional regimen (de Gramont) is the preferred fluoropyrimidine 
monotherapy. Capecitabine is a safe oral alternative to 5-FU. 
2.2 Irinotecan (table 1) 
Irinotecan is a topoisomerase I inhibitor and has demonstrated efficacy in mCRC as a single 
agent or in association with a fluoropyrimidine. Irinotecan in monotherapy showed 
superiority to best supportive care alone after 5-FU failure. A randomized trial showed that 
the OS was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year 
survival in the irinotecan group versus 13.8% in the supportive-care group. Quality of life 
was also better with less tumor related symptoms. In this trial, irinotecan was given every 
three weeks (Cunningham et al. 1998).  
A randomized trial showed an advantage in RR, time to progression (TTP) and median 
survival for combined treatment with irinotecan/5-FU/LV over 5-FU/LV alone in first-line 
mCRC. An infusional regimen was used (the Douillard regimen). Treatment was given 
weekly or every two weeks. There were more toxicities in the irinotecan arm (diarrhea and 
neutropenia) but they were manageable (Douillard et al. 2000). Results of the BICC-C study 
suggest that the infusional regimen (FOLFIRI) is associated with better PFS and less 
toxicities compared to the bolus regimen (IFL). 
The use of oral capecitabine associated with irinotecan (CapeIRI) was also assessed in the 
BICC-C study. It was compared to FOLFIRI and IFL. It was associated with more toxicities 
and less efficacy (Fuchs et al. 2007). 
Late diarrhea and neutropenia are the main dose-limiting toxicities from irinotecan. UGT1A1 
polymorphism predicts irinotecan toxicity. Irinotecan can also cause early-onset symptoms of 
cholinergic excess including diarrhea, abdominal cramping, lacrimation, rhinitis and 
salivation.  
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Regimen Irinotecan Leucovorin 5-FU*/capecitabine Schedule 
FOLFIRI 
Fuchs et al. 
2007 
 
 180 mg/m2 IV 
over 90 min 
day 1 
 
400 mg/m2 IV 
over 2 h day 1 
*400 mg/m2 
IV bolus day 1; 
2400 mg/m2 IV 
continuous 
infusion over 46 h 
Every two 
weeks 
IFL 
Saltz et 
al.2000 
125 mg/m2 IV 
bolus 
20 mg/m2 IV 
bolus 
*500 mg/m2 IV 
bolus 
Weekly for 
four weeks 
every six 
weeks 
mIFL   
Fuchs et al. 
2007 
125 mg/m2 IV 
over 90 min 
on 
days 1 and 8 
 
20 mg/m2 IV 
bolus 
on days 1 and 8
*500 mg/m2 IV 
bolus on days 1 
and 8 
Every three 
weeks 
CapeIRI 
Fuchs et al. 
2007 
250 mg/m2 IV 
over 90 
minutes day 1 
 Capecitabine by 
mouth 1000mg/m2 
twice a day on 
days 1 to 14 
Every three 
weeks 
Table 1. Irinotecan Regimens 
2.3 Oxaliplatin (table2) 
In 1998, the platinum derivative, oxaliplatin when given together with 5-FU was shown to 
have significant activity in mCRC (deBraud et al. 1998). The activity of oxaliplatin alone in 
mCRC is low (Rothenberg et al. 2003). In 2000, a study showed better PFS and RR with the 
addition of oxaliplatin to 5-FU/LV compared to 5-FU/LV infusional regimen alone as first-
line treatment in advanced colorectal cancer (de Gramont et al. 2000). 
The combination of oxaliplatin and oral capecitabine (XELOX or CAPOX) has also been 
studied and compared to other fluoropyrimidine/oxaliplatin combinations in multiple 
randomized studies.  A pooled analysis of randomized trials comparing first-line CAPOX to 
oxaliplatin in combination to infusional 5-FU/LV showed that CAPOX resulted in lower RR, 
but this did not affect PFS and OS. The toxicity analysis showed thrombocytopenia and 
hand-foot syndrome were consistently more prominent with the CAPOX regimens 
(Arkenau et al. 2008). CAPOX may be considered in patients where ambulatory infusion is 
not possible or refused. 
In 2004, Tournigand and colleagues randomly assigned previously untreated patients to 
FOLFOX 6 or FOLFIRI. At progression, irinotecan was replaced by oxaliplatin or oxaliplatin 
by irinotecan. Both strategies showed equivalent RR (about 55%) and median survival (20.6 
and 21.5 months). Nausea, mucositis and alopecia were more common with FOLFIRI while 
neutropenia and paresthesias were more common with FOLFOX (Tournigand et al. 2004). 
An Italian study showed similar findings (Colucci et al. 2005). 
Thus, using FOLFOX or FOLFIRI in first-line treatment and then switching to the alternate 
regimen at progression or treatment intolerance is widely accepted. The decision of 
choosing one regimen over the other will be influenced by toxicity profile and patient 
preference. 
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One of the main concerns with the use of oxaliplatin is neurotoxicity. Acute neurotoxicity 
and cumulative sensory neuropathy are described. The acute neurotoxicity typical 
symptoms are dysesthesias of hands, feet and perioral region. More rarely, pharyngeal 
dysesthesias can be observed. These symptoms are generally triggered by cold, are 
associated with higher doses of oxaliplatin and are infusion-rate dependant. In 2008, Petrioli 
and colleagues suggested a prolonged infusion time to reduce the acute toxicity (Petrioli et 
al. 2008). This acute toxicity seems to be related to hyperexcitability of the peripheral nerves 
which has been attributed to disruption in cell membrane ion channels (Wilson et al. 2002; 
Park et   al. 2009). In contrast, the cumulative neuropathy is generally sensory, symmetrical 
and without motor involvement. Oxaliplatin-induced cumulative sensory neuropathy 
occurs after several cycles of therapy (Cassidy et al. 2002). In about three fourths of patients, 
neurotoxicity is reversible with a median time to recovery of 13 weeks after treatment 
discontinuation. Strategies have been developed to prevent oxaliplatin-induced cumulative 
neurotoxicity. First, new schedules of administration were investigated. The Optimox-1 
study randomly assigned patients to FOLFOX 4 (oxaliplatin 85 mg/m2) until progression or 
to six cycles of FOLFOX 7 (oxaliplatin 130mg/m2) followed by maintenance 5FU-LV for 12 
cycles. FOLFOX 7 was then reintroduced for non progressive patients. RR, PFS and survival 
were similar in both arms. Grade 3 and 4 neuropathy was reduced in FOLFOX 7 arm after 
the sixth cycle even though it occurred earlier. The conclusion was that oxaliplatin can be 
safely stopped after six cycles in a FOLFOX 7 regimen (Tournigand et al. 2006). The 
Optimox-2 study compared a chemotherapy-free interval with maintenance 5-FU/LV after six 
cycles of modified FOLFOX 7 (mFOLFOX7) chemotherapy in the first-line treatment of mCRC. 
mFOLFOX 7 was reintroduced for patients with progressive disease in both arms. Duration of 
disease control (DDC) and PFS were better in the maintenance arm (Chibaudel et al. 2009). 
Thus oxaliplatin-free intervals are feasible but complete discontinuation of chemotherapy may 
be associated with inferior outcomes. Secondly, the benefit of use of IV calcium (Ca) and 
magnesium (Mg) in order to diminish neuropathy symptoms was suggested in randomized 
trials. In 2011, Grothey and colleagues showed that IV Ca/Mg is an effective neuroprotectant 
against oxaliplatin-induced cumulative neuropathy in adjuvant colon cancer. The incidence of 
grade 2 or greater cumulative sensory neurotoxicity was significantly reduced. The onset of 
grade 2 or greater sensory neurotoxicity was also delayed in patients receiving Ca/Mg 
(Grothey et al. 2011). This study had a low statistical power due to early closure of the trial 
because preliminary reports from another trial (CONcePT trial) that initially suggested 
decreased response rates for patients getting Ca/Mg (Hochster et al. 2007). This was later 
proven untrue by an independent radiologic review.  
2.4 Other chemotherapy combinations (table 2) 
The combination of oxaliplatin and irinotecan (IROX) has been assessed in first and second 
line setting. In the first-line setting, IROX was shown to be inferior and more toxic in elderly 
patients compared to FOLFOX (Sanoff et al. 2008) and equivalent to FOLFIRI (Fischer von 
Weikersthal et al.2011). In the second-line setting, IROX was compared to a triple regimen of 
5FU/LV with alternating irinotecan and oxaliplatin. RR (23 versus 6 percent) and median 
survival (12.3 versus 9.8 months) were better with IROX but the doses of irinotecan and 
oxaliplatin were smaller in the triple therapy arm (Bécouarn et al. 2001). The efficacy of 
FOLFOXIRI regimen has been evaluated in two randomized studies. An Italian study 
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showed better RR (41 versus 66 percent), PFS (9.8 versus 6.9 months) and OS (22.6 versus 
16.7 months) for FOLFOXIRI compared to FOLFIRI in the first-line setting. This was in a 
selected population of patients in good general condition and with favorable features. More 
toxicities were reported in the FOLFOXIRI arm especially in terms of neutropenia and 
neurotoxicity (Falcone et al.2007). This benefit and its cost in terms of toxicities were 
confirmed in a systematic review (Montagnani et al. 2010). In contrast, a Greek phase 3 
randomized failed to show benefits to FOLFOXIRI when compared to FOLFIRI (Souglakos 
et al. 2006). However, compared to the Italian trial, lower doses of oxaliplatin, irinotecan and 
5-FU were used. 
 
Regimen Oxaliplatin Irinotecan Leucovorin 5-FU/cape Schedule 
CAPOX 
Hochster et al. 
2008 
130mg/m2 IV 
on day 1  
 
  capecitabine 1,000 
mg/m2 orally twice 
daily on days 1 to 15  
Every 
three 
weeks 
IROX 
Goldberg et al. 
2004 
85mg/m2  
 
200 mg/m2   Every 
three 
weeks 
FOLFOX 4      
Goldberg et al. 
2004 
 
85 mg/m2 on 
day 1 
 
 200 mg/m2 
day 1 
bolus FU 
400 mg/m2 followed 
by FU 600 mg/m2 in 
22-hour infusions on 
days 1 and 2 
Every  
two  
weeks 
FOLFOX 6 
Tournigand et al. 
2004 
 
100 mg/m2 
day 1 
 400 mg/m2 
day 1 
bolus FU 400mg/m2 
followed by infusion 
2400-3000 mg/m2 
over 46 hours 
Every 
 two weeks 
FOLFOX 6 
modified        
Hochster et al. 
2008 
 
85 mg/m2 day 
1 
 400 mg/m2 
day 1 
bolus FU 400mg/m2 
followed by infusion 
2400 mg/m2 over 46 
hours 
Every  
two  
weeks 
bFOL 
Hochster et al. 
2008 
 
85 mg/m2 on 
days 1 and 15
 20 mg/m2 
days 1, 8 and 
15 
500 mg/m2 push days 
1,8 and 15 
Every  
four weeks 
FOLFOX 7 
Tournigand et al. 
2006 
 
130 mg/m2 
day 1 
 400 mg/m2 
day 1 
infusion 2400 mg/m2 
over 46 hours 
Every  
two  
weeks 
FOLFOX 7 
modified 
Chibaudel et al. 
2009 
100 mg/m2 
day 1 
 400 mg/m2 
day 1 
infusion 3000  mg/m2 
over 46 hours 
Every  
two  
weeks 
FOLFOXIRI 
Falcone et al. 2007
85 mg/m2 day 
1 
165 mg/m2 
day 1 
200 mg/m2 
day 1 
Infusion 3200 mg/m2 
over 48h 
Every  
two  
weeks 
Table 2. Oxaliplatin Regimens 
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3. Targeted therapies 
Targeted cancer therapies are drugs that block the growth and spread of cancer by 
interfering with specific molecules involved in tumor growth and progression. 
Bevacizumab, cetuximab and panitumumab are three monoclonal antibodies which have 
known efficacy in mCRC. 
3.1 Angiogenesis inhibitors 
3.1.1 Bevacizumab 
Bevacizumab is a monoclonal humanized antibody targeting the VEGF. It is assumed that 
bevacizumab normalizes the vascular environment and improves the chemotherapy 
delivery to the tumor.  
Bolus IFL (irinotecan/5-FU/LV) plus bevacizumab (5mg/kg) was compared to IFL plus 
placebo in previously untreated patients with mCRC. They observed statistically better RR, 
PFS and OS (20.3 versus 15.6 months). This was the pivotal study which led to the approval 
of bevacizumab in the treatment of mCRC. Grade 3-4 high blood pressure (HBP) was 
significantly increased in the bevacizumab arm (Hurwitz et al. 2004). FOLFIRI regimen has 
however gained acceptance over the bolus IFL regimen due to a more favorable toxicity 
profile. The BICC-C trial showed a significant advantage in terms of median survival with 
FOLFIRI plus bevacizumab compared to mIFL plus bevacizumab (28 versus 19 months, 
p=0.037) (Fuchs et al. 2007).  Several trials have also addressed the benefit of adding 
bevacizumab to an oxaliplatin-based regimen. In a phase 2 cohort study (TREE-2), three 
oxaliplatin-containing regimens (FOLFOX, bolus 5FU and oxaliplatin-bFOL, CAPOX) were 
investigated in association with bevacizumab. Median survivals were respectively 26.1, 20.4 
and 24.6 months (Hochster et al. 2008). Median OS was 23.7 months for the combined group 
treated with bevacizumab compared to 18.2 months for patients who did not received 
bevacizumab.The benefit of adding bevacizumab to oxaliplatin-containing chemotherapy 
appeared however to be more modest in the NO16966 trial. The addition of bevacizumab to 
FOLFOX4 or XELOX resulted in an increase of PFS of 1.4 months but the superiority of 
bevacizumab was statistically evident only in the XELOX subgroup (p=0.0026). 
Additionally, the OS significance did not reach statistical difference (21.3 months vs. 19.9 
months) and the RR was similar in both groups (47% vs. 49%) (Saltz et al. 2008). The use of 
bevacizumab in first line is nevertheless widely accepted with either FOLFOX or FOLFIRI. 
In a phase 2 randomized study 5-FU/LV plus placebo was compared to 5-FU/LV plus 
bevacizumab. The bevacizumab-based treatment showed significant better PFS and non 
significant better OS (Kabbinavar et al. 2005). Thus, 5-FU/LV plus bevacizumab remains an 
option for patients with contraindications to other regimens. 
The addition of bevacizumab in second-line treatment was assessed in the ECOG 3200 trial. 
Patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned 
to receive FOLFOX4 in combination with bevacizumab (at 10 mg/kg), FOLFOX4 or 
bevacizumab alone. This study showed better PFS and OS in the FOLFOX4 plus 
bevacizumab arm. No activity was shown with bevacizumab alone (Giantonio et al. 2007). 
In contrast, there is no strong enough evidence to continue bevacizumab beyond 
progression in first-line treatment although favorable data is suggested by the BRITE study. 
This cohort study showed encouraging survival rates in patients who received post-
progression chemotherapy with continued bevacizumab (Grothey et al. 2008). 
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Bevacizumab is associated with several toxicities such as proteinuria, bleeding, HBP, arterial 
thromboembolic events (ATE) and gastrointestinal perforations (Kabbinavar et al. 2005). 
Thus high risk patients with comorbidities such as elderly patients and patients with 
historic of ATE or bleeding should be identified and carefully monitored if bevacizumab is 
administered. Also, because VEGF is involved in wound healing, bevacizumab should be 
stopped at least five weeks before any surgery. 
3.2 Anti-EGFR monoclonal antibodies 
Cetuximab and panitumumab are monoclonal antibodies targeting the extracellular domain 
of the EGFR (epidermal growth factor receptor).  KRAS mutations cause permanent 
activation of the downstream cascade and result in failure to respond to anti-EGFR 
monoclonal antibodies (Bardelli et al. 2010) (figure 1). KRAS mutations are detected in 
approximately 40% of mCRC. These mutations are mainly found in codons 12 and 13. 
Recent studies suggest however that not all mutations confer the same resistance to anti-
EGFR therapy. Nevertheless, KRAS mutation is a predictive biomarker for anti-EGFR 
therapy and tumor KRAS status should be determined whenever anti-EGFR therapy is 
considered in the treatment of mCRC. According to ASCO’s provisional clinical opinion, all 
patients with metastatic colorectal carcinoma who are candidates for anti-EGFR antibody 
therapy should have their tumor tested for KRAS mutations in an accredited laboratory. If 
KRAS mutation in codon 12 or 13 is detected, then patients with metastatic colorectal 
carcinoma should not receive anti-EGFR antibody therapy as part of their treatment (Allegra 
et al. 2009). 
Other mutations probably confer resistance to anti-EGFR therapy. BRAF mutation is found 
in 5 to 10 % of colorectal cancer tumors. KRAS and BRAF mutations are mutually exclusive. 
The BRAF mutation has been recognized as a negative prognostic marker but recent data 
does not confirm it as a negative predictive marker for anti-EGFR therapy. PIK3CA 
mutations/PTEN expression, amphiregulin and epiregulin are other potential predictive 
biomarkers but further supportive, preferably prospective, studies confirming their role as 
predictive biomarkers for anti-EGFR therapy would be necessary before considering their 
use in routine clinical practice in this regard.  
 
 
Fig. 1. EGFR Signal Transduction 
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Cetuximab is associated with severe infusion reaction in three percent of patients. Ninety 
percent occur during the first infusion and generally in the three first hours. Premedication 
with anti H1 antagonist and/or glucocorticoid is recommended (Wilke et al. 2008). 
Panitumumab is generally associated with less infusion reaction because of its 100% human 
origin. Cetuximab and panitumumab may be also associated with a magnesium-wasting 
syndrome. Serum levels of this electrolyte should be carefully monitored during treatment. 
Acneiform eruption occurs in two third of patients treated anti-EGFR molecules. Some 
studies suggest benefit from using prophylactic antibiotics such as minocyline or 
doxycycline and topical application of hydrocortisone-based cream (Scope et al. 2007; 
Lacouture et al. 2010). 
3.2.1 Cetuximab (table 3) 
Cetuximab is a chimeric (mouse/human) monoclonal antibody against the EGFR. In 
mCRC, cetuximab has shown efficacy in monotherapy as well as in combination with 
chemotherapy. It can be used in previously mCRC treated patients or in first-line therapy. 
In 2007, cetuximab alone was compared to best supportive care (BSC) in the CO-17 trial. 
Patients had immunohistochemically detectable EGFR, previously been treated with 
fluoropyrymidines, irinotecan and oxaliplatin or had contraindications to treatment with 
these drugs. Survival was significantly better in the cetuximab arm (6.1 vs. 4.6 months). 
Quality of life was better preserved in the cetuximab group. Cetuximab was associated with 
a skin rash; grade 2 or higher grade rashes were strongly associated with improved survival 
(Jonker et al. 2007). In a subsequent analysis, in patients with mutated KRAS tumors, there 
was no significant difference between those who were treated with cetuximab and those 
who were treated with best supportive care. For wild-type (wt) KRAS patients, PFS (3.7 
versus 1.9 months) and median OS (9.5 versus 4.8 months) were significantly improved by 
treatment with cetuximab as compared with best supportive care alone (Karapetis et al. 
2008). 
In the BOND study, a randomized phase 2 trial, irinotecan plus cetuximab was compared to 
cetuximab alone for patients refractory to irinotecan. RR and TTP were significantly better in 
the irinotecan plus cetuximab arm (22.9% vs. 10.8% and 4.1 vs. 1.5 months). There was a 
trend for better survival also in this arm as well (Cunningham et al. 2004).   
In the EPIC trial, adding cetuximab to irinotecan after first-line fluoropyrimidine and 
oxaliplatin treatment failure, improved RR (16.4 percent versus 4.2 percent), PFS  
(4.0 versus 2.6 months) and quality of life compared with irinotecan alone (Sobrero et al. 
2008; table 3). 
Trials have also evaluated the efficacy of cetuximab in combination with chemotherapy in 
first-line treatment of mCRC. In the phase III CRYSTAL trial, the efficacy of cetuximab 
plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) was investigated as first-line 
treatment for metastatic colorectal cancer. There was a significant advantage in RR, PFS 
and OS for the cetuximab group, but this benefit was limited to KRAS-wt patients (Van 
Cutsem et al. 2010).  
In the randomized phase II multicenter OPUS trial, the addition of cetuximab to FOLFOX4 
was associated with improved outcomes compared to FOLFOX4 alone in first-line 
treatment. A statistically significant better chance of response and PFS was shown in 
patients with KRAS wild-type tumors (Bokemeyer et al. 2009; table 3). Patients with mutant 
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KRAS tumors did not benefit, and may actually have been harmed, with the addition of 
cetuximab (RR of 33% vs. 49% in the FOLFOX4 alone group (p=0.106)). The phase III COIN 
trial is another important study which has evaluated the effect of addition of cetuximab to 
first-line oxaliplatin-based regimens treatment for advanced colorectal cancer.  The choice of 
fluoropyrimidine (either 5-FU or capecitabine) was decided by the treating physician prior 
randomization (66% of the patients received oxaliplatin plus capecitabine). In patients with 
wt-KRAS tumor, the addition of cetuximab to oxaliplatin- based chemotherapy was 
associated with a small increase in best overall response (64% vs. 57%, P=0.049). In contrast 
to CRYSTAL and OPUS studies, however, the addition of cetuximab was not associated 
with any significant improvement in OS or PFS. (Maughan et al. 2011). Discrepancy between 
these studies remains difficult to explain.   
3.2.2 Panitumumab (table 3)
 
Panitumumab is a fully human monoclonal antibody targeting the extracellular domain of 
EGFR. Similarly to cetuximab, panitumumab has shown efficacy in previously mCRC 
treated patients as well as in first-line therapy. 
In patients refractory to 5-FU, irinotecan and oxaliplatin, panitumumab monotherapy 
showed significantly improved PFS from 7.3 to 8 weeks (p<0.001) and RR (10 percent versus 
0 percent) compared to BSC alone. There was no OS benefit, likely due to panitumumab use 
after crossover in the BSC alone. Skin toxicities, hypomagnesaemia, and diarrhea were the 
most common toxicities observed (Van Cutsem et al. 2007). In this study, the effect on PFS in 
the wt-KRAS group was significantly higher than in the mutant group. Median PFS in the 
wt-KRAS group was 12.3 for panitumumab versus 7.3 weeks for BSC. RR was 17 percent for 
wt-KRAS versus 0 percent for patients with mutant KRAS tumors. This showed that 
panitumumab monotherapy efficacy is confined to wt-KRAS tumors and that this status 
should be considered in selecting patients for panitumumab monotherapy (Amado et al. 
2008). In 2010, the FOLFIRI/panitumumab combination was compared to FOLFIRI alone  
in second-line treatment. In the KRAS-wt patients, when panitumumab was added to 
FOLFIRI median PFS was 5.9 months versus 3.9 months for FOLFIRI alone (p=0.004)(Peeters 
et al. 2009). 
Panitumumab, in conjunction with chemotherapy regimen, has also been evaluated in first-
line therapy for mCRC. In 2010, Douillard and colleagues compared FOLFOX 4 and 
panitumumab versus FOLFOX 4 alone as first-line chemotherapy for previously untreated 
mCRC (PRIME study). In the KRAS-wt patients, panitumumab-FOLFOX4 combination 
significantly improved PFS compared with FOLFOX4 (median PFS, 9.6 v 8.0 months, 
respectively; p=0.02).  In the KRAS-mutant patients, outcome was significantly worse with 
panitumumab underscoring the importance of KRAS screening (Douillard et al. 2010). 
Several studies have assessed the use of a dual antibody modality. The PACCE study 
evaluated the addition of panitumumab to bevacizumab and chemotherapy (oxaliplatin- 
and irinotecan-based) as first-line treatment for mCRC (Hecht et al. 2009). This study was 
stopped due to an interim analysis showing inferior PFS and more toxicities in the 
panitumumab arm. The CAIRO 2 study assigned untreated metastatic colorectal cancer to 
capecitabine, oxaliplatin, and bevacizumab or the same regimen plus weekly cetuximab. 
PFS was worse in dual antibody therapy (Tol et al. 2009).These results suggest that dual 
antibody therapy should not be considered outside further clinical trials. 
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Trial Agent Line Chemotherapy Results (*KRAS-wt patients) 
CRYSTAL 
Van Cutsem 
et al. 2011 
Cetuximab First FOLFIRI Median PFS*:  9.9 vs. 8.4 months 
 HR 0.696 (p=0.0012) 
Median OS*: 23.5 vs. 20.0 months 
HR 0.796 (p=0.0093) 
 
OPUS 
Bokemeyer et 
al. 2009 
Cetuximab First FOLFOX 4 Overall RR*: 61% vs. 37% 
(p=0.011) 
Median PFS*: 7.7 vs. 7.2 months 
(p=0.0163) 
COIN 
Maughan et 
al. 2011 
Cetuximab First Oxaliplatin with 
5FU or capecitabine 
ORR*: 64% vs. 57% (p=0.049)  
No significant improvement in OS 
or PFS with the addition of 
cetuximab 
PRIME 
Douillard et 
al. 2010 
 
Panitumumab First FOLFOX 4 Median PFS*: 9.6 vs. 8 months 
(p=0.02) 
EPIC 
Sobrero et 
al.2008 
Cetuximab Second Irinotecan PFS: 4 vs. 2.6 months (p<0.0001) 
RR: 16.4% vs. 4.2% (p<0.0001) 
OS: 10.7 vs. 10.0 months (p=0.71) 
but 46.9% of the patients in the 
irinotecan group received 
cetuximab after trial. 
(KRAS unselected) 
STUDY 181 
Peeters et al. 
2010 
Panitumumab Second FOLFIRI Median PFS*: 5.9 vs. 3.9 months 
(p=0.004)  
Table 3. Randomized Trials of Anti-EGFR-chemotherapy Association 
4. Local recurrence 
The treatment of locally recurrent disease largely depends on prior treatments. Whether the 
patient had prior surgery and/or radiation will determine the therapeutic approach. 
Surgery alone may be an option if negative surgical margins can be achieved. Extensive 
surgery is generally required. Combined therapies including chemotherapy and radiation (if 
prior radiation was not administered) are favored. In this setting the addition of 
chemotherapy to radiation before surgery improved local control, time to treatment failure, 
and cancer-specific survival compared with RT alone in a Norwegian phase 3 randomized 
study (Braendengen et al. 2008). Still this data has to be considered carefully because the 
patients in this study had primary unresectable tumors as well as local recurrences and that 
prior radiation was not allowed. Patients with local recurrence were more likely to be 
unresectable after preoperative treatment. Trends to improved local control were seen in a 
retrospective study from the Mayo clinic with the addition of 5-FU to external beam 
radiotherapy, intraoperative electron beam and surgery (Gunderson et al. 1996). 
5. Summary and recommendations  
Striking advances have been made in the treatment of metastatic colorectal cancer in the 
past fifteen years. In 2004, Grothey and colleagues reviewed seven published phase III trials 
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in advanced CRC. Their conclusion was that the three active drugs in mCRC (5-FU/LV, 
irinotecan and oxaliplatin) should be available to all patients in order to maximize the OS 
(Grothey et al. 2004). For patients with good performance status, combination therapy 
(FOLFOX or FOLFIRI) should be preferred as first-line chemotherapy. The choice of 
regimen should be based on the different toxicity profile of these two regimens. Fragile 
patients are not candidates for combination therapy but can benefit from treatment with 
fluoropyrimidine monotherapy. Infusion regimens are associated with less toxicity and 
should be used in any regimen. The use of oral capecitabine in regimens such as CAPOX is 
also a valid option for patients for whom infusion is not possible or refused. Different 
strategies can be used in an attempt to prevent oxaliplatin-induced neuropathy. It remains 
unclear if a combination regimen such as FOLFOXIRI is superior to FOLFOX or FOLFIRI 
combined with bevacizumab or an anti-EGFR monoclonal antibody. FOLFOXIRI is 
associated with significant toxicity and its use is not yet standard in first-line treatment of 
mCRC. The addition of bevacizumab, a monoclonal antibody targeting the VEGF, is now 
widely recommended with FOLFIRI, FOLFOX or fluoropyrimidine monotherapy in first-
line therapy of mCRC for patients without contraindications to this agent.  The use of 
bevacizumab in second-line setting is also recommended in patients who did not receive 
this agent in first-line treatment. The benefit of its use beyond progression remains 
controversial and is not presently recommended. Bevacizumab is associated with potentially 
serious toxicities so careful attention and monitoring of expected side effects is mandatory. 
Anti-EGFR monoclonal antibodies, cetuximab and panitumumab, are associated with 
improved outcomes when used as single agents as salvage therapy in patients with 
chemotherapy-refractory mCRC and when used for first-line and second-line therapy of 
mCRC in conjunction with chemotherapy regimens. However, their benefit is restrained to 
patients whose tumor does not harbour KRAS mutation.  It is unknown whether adding 
EGFR inhibitors to initial therapy or using it in a sequential approach as a component of 
second or third –line therapy gives better results. Also, for now, it is not clear whether 
bevacizumab or anti-EGFR inhibitor should be preferentially added to first-line therapy. 
Indeed, chemotherapy plus bevacizumab currently represents the most widely accepted 
standard for first-line treatment of mCRC.  Results from the current North American 
CALGB/SWOG cooperative group trial of best chemotherapy plus either bevacizumab or 
cetuximab in untreated KRAS-wt metastatic colorectal patients will help in guiding this 
decision. Although there are no trials directly comparing panitumumab to cetuximab, these 
agents appear to have comparable efficacy and they are probably interchangeable. 
Treatment must be individualized as always, taking into account goals of therapy, KRAS 
mutation status, and the toxicity profiles of each agent.  Inclusion of patients in clinical trials 
should always be encouraged if possible. 
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